A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
NCT06465186 on ClinicalTrials.gov · last registry update 2026-09-21
Finished 3 August 2026, after enrolling 85 people. Primary outcome, as filed: Change from Baseline in Liver Fat Content (LFC) at Week 28. efinopegdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 3 times since then.
- Status
- COMPLETED
- Phase
- P2
- Drug
- efinopegdutide
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Enrollment
- 85
- Started
- 2024-07-12
- Primary completion
- 2026-08-03 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-21 | Status changed | ACTIVE_NOT_RECRUITING → COMPLETED |
| 2026-09-21 | Reporting date moved | 2026-08-06 → 2026-08-03 |
| 2026-09-21 | Enrollment changed | 80 → 85 (+5) participants |
Primary outcome
Change from Baseline in Liver Fat Content (LFC) at Week 28
Conditions studied
Non-alcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis · NAFLD · Metabolic Dysfunction-associated Steatotic Liver Disease · Metabolic Dysfunction-associated Steatohepatitis
Every field above is taken directly from the registry record. See all detected changes across the class, or the efinopegdutide page for this molecule’s full trial and approval history.